Investment
Features
FeesSafety
Academy
More
Pluang+

Compare FedEx Corporation (FDX) vs Heron Therapeutics Inc (HRTX) Price & Performance

FedEx CorporationTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

FedEx Corporation vs Heron Therapeutics Inc — how do they compare? FedEx Corporation trades at $322.84 (market cap $76.28B), while Heron Therapeutics Inc trades at $0.34 (market cap $61.47M). The key difference: FedEx Corporation is far larger — about 1240.9× Heron Therapeutics Inc's market cap, and FedEx Corporation pays a 1.51% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.

FDXHRTX
Market Cap
$76.28B$61.47M
Sector
IndustrialsHealth
52-Week High
$338.75$1.49
52-Week Low
$180.51$0.32
Enterprise Value
$105.91B$168.21M
Dividend Yield
1.51%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

FedEx Corporation

FedEx (FDX) trades at $325.08, up 2.04% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a consensus price target of $360.27 highlight positive momentum. The company's network transformation and focus on premium shipments are driving operational improvements, though revenue has been flat year-over-year. Cash flow trends show a projected rebound in 2026, with net cash flow turning positive.

The outlook for FDX is favorable, supported by cost-cutting initiatives and strategic shifts toward high-margin business. Key risks include competitive pressures and macroeconomic sensitivity. With 57% of analysts rating it a buy and institutional interest growing, the stock presents a compelling opportunity for growth-oriented investors, albeit with exposure to economic cycles.

Heron Therapeutics Inc

HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.

The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About FedEx Corporation

FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.

Read more on FDX

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX